Prices are updated after-hours

Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

Ritonavir   save search

Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster
Published: 2022-10-17 (Crawled : 13:00) - globenewswire.com
SRNE | $0.02 33.33% -8.85% 97K twitter stocktwits trandingview |
Health Technology
| | O: 4.48% H: 11.43% C: 9.29%

sti-1558 covid-19 treatment trials global study
Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster
Published: 2022-08-03 (Crawled : 13:20) - globenewswire.com
SRNE | $0.02 33.33% -8.85% 97K twitter stocktwits trandingview |
Health Technology
| | O: 0.77% H: 8.32% C: 2.3%

sti-1558 covid-19 treatment study
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster
Published: 2022-06-03 (Crawled : 15:20) - biospace.com/
SRNE | $0.02 33.33% -8.85% 97K twitter stocktwits trandingview |
Health Technology
| | O: 8.18% H: 2.33% C: -0.58%

sti-1558 covid-19 treatment therapeutics
Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19
Published: 2022-04-04 (Crawled : 13:20) - biospace.com/
ALGS | $0.829 0.66% -0.39% 220 twitter stocktwits trandingview |
Health Technology
| | O: 0.5% H: 8.0% C: 3.5%

alg-0975 covid-19 treatment drug therapeutics
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries
Published: 2022-03-01 (Crawled : 10:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.02% 2.9M twitter stocktwits trandingview |
Health Technology
| | O: 0.99% H: 0.0% C: 0.0%

europe application authorization submission
Gainers vs Losers
61% 39%

Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M twitter stocktwits trandingview |

BHIL | $0.1793 -4.37% 19.24% 340K twitter stocktwits trandingview |
Agriculture, Forestry, Fishing ...

UMAC | $1.48 -1.33% 14.87% 20K twitter stocktwits trandingview |

CI | $352.28 -0.11% 13.53% 2 twitter stocktwits trandingview |
Health Services

CIG.C | $2.89 -1.37% 12.8% 2.3K twitter stocktwits trandingview |
n/a

MTH | $154.69 -2.21% 12.68% 450K twitter stocktwits trandingview |
Consumer Durables

HCP | News | $31.41 7.75% 11.26% 17M twitter stocktwits trandingview |

TSLA | News | $162.13 12.06% 10.13% 170M twitter stocktwits trandingview |
Consumer Durables

BMTX 4 | $1.545 0.98% 10.03% 2.5K twitter stocktwits trandingview |
Information

TAL | $12.26 0.57% 9.22% 12M twitter stocktwits trandingview |
Consumer Services


Your saved searches
Save your searches and get alerts when important news are released.